Molecular Tumor Board

• Jill Kolesar, PharmD, MS, Co-Director
• Rachel Miller, MD, Co-Director

Molecular Tumor Board Office Phone: 1-844-622-0341

Click here to contact the tumor board by email, or email Dr. Kolesar directly.

---

Administrative Office

Marissa Schuh, marissa.schuh@uky.edu

Molecular Tumor Board Manager

1-844-622-0341

The Molecular Tumor Board (MTB) meets:

• 12 p.m.
• Every first and third Tuesday
• Room CC 457, Ben F. Roach Building

Off-site participants can call in via UK Telehealth. Email the MTB manager to be added to the call in list.

Some MTB meetings will include a 15-minute informational update on Precision Medicine. See Schedule for Topics and Speakers.

To schedule a case presentation, review the details in the Case Submission section. All cases must be submitted to MTB seven days prior to meeting date.

MTB Meeting Schedule

Case Submission Date	Meeting Date	15 Minute Update Topic	Speaker
01/09/18	01/16/18
01/30/18	02/06/18
02/13/18	02/20/18
02/27/18	03/06/18
04/10/18	04/17/18
04/24/18	05/21/18
05/08/18	05/15/18
05/29/18	06/05/18
06/12/18	06/19/18
06/26/18	07/03/18
07/10/18	07/17/18
07/31/18	08/07/18
08/14/18	08/21/18
08/28/18	09/04/18
09/11/18	09/18/18
09/25/18	10/02/18
10/09/18	10/16/18
10/30/18	11/06/18
11/13/18	11/20/18
11/27/18	12/04/18
12/11/18	12/18/18

Continuing Medical Education (CME)

If clinicians or pharmacists want to obtain CE Credit for this meeting, they must attend the meeting in person or via teleconference, then enter the provided access code on the CE Central website. Any questions or concerns regarding CE Credit can be directed to the MTB Manager at mtb@uky.edu.  

Policy on Disclosure

It is the policy of the Markey Cancer Center that the faculty, authors, planners and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation.

The MTB Journal Club meets to evaluate current research regarding oncology-based precision medicine at 1 p.m. every first Tuesday in Room CC 457, Ben F. Roach Building.

• 1 p.m.
• Every first Tuesday
• Room CC 457, Ben F. Roach Building

To find presentations from our Journal Club meetings, visit the MTB's References section.

03/06/18	Danielle Corbett, PhamD	Outsmarting our Genes: Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
04/03/18
05/15/18	Laura Cannon, PharmD	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
06/05/18
07/03/18
08/07/18
09/04/18
10/02/18
11/06/18
12/04/18

Cases must be submitted at least seven days prior to the meeting date.

Genomics reports from UK HealthCare or external sources (Foundation, MATCH, etc.) can be submitted.

A patient's genomic report is required for case submission. Please see how to order a genomic report through UK HealthCare under Order a Genomic Report below. 

If you already have a genomic report, fill out the case submission form online, or download the form here.

The patient’s genomic report can be sent to MTB by email.

When the case submission and genomic report are received, the MTB manager will schedule the case for presentation and invite the treating clinician to the meeting.

Treatment recommendations will be discussed at the MTB meeting. Recommendation letters will be faxed and/or mailed or uploaded into the electronic health record per the preference of the submitting physician. Specify method of results reporting on the case submission form.

Note: There is no cost to submit a case to the Markey Cancer Center Molecular Tumor Board.

Genomic reports can be ordered through the Clinical Molecular and Genomic Pathology department. There is a comprehensive solid tumor panel, some gene-specific hematological panels as well as a larger hematological malignancy panel. Please see the information forms below on the methodology of the panels and what genes are included in the panels. 

To order a genomic report, the clinical staff must:

1. Fill out the Requisition Form.
2. Send tissue blocks to the address listed on the form: 800 Rose St. HA619, Lexington, KY 40536-0293

If you have any questions about ordering a genomic panel for your patient, please contact the Clinical Molecular and Genomic Pathology department at (859) 323-5327 or cmgp@uky.edu.

• Download the Solid Tumor Test Requisition Form (PDF, 47 KB)
• Download the Hematologic Malignancy Test Requisition Form (PDF, 80 KB)

Solid tumor panels:

Comprehensive Solid Tumor Panel (198 Genes) (PDF, 119 KB)

Hematologic Malignancy Panels:

FLT3-ITD and FLT3-TKD (PDF, 18 KB)

NPM1 (PDF, 141 KB)

CEBPA (PDF, 150 KB)

Hematologic Malignancy Panel (94 Genes) (PDF, 115 KB)

The Molecular Tumor Board currently has two prospective clinical trials evaluating integration of Precision Medicine into cancer therapeutics.

• Part 1:  A prospective observational cohort study evaluating outcomes of genomic testing in patients with poor prognosis cancer.
• Part 2: A therapeutic phase 2 sub-study evaluating genomic testing in human cancer and outcomes of targeted therapies recommended by an institutional multidisciplinary molecular tumor board in patients with poor prognosis cancer.

Researchers who are interested in using the data or specimen collected under these protocols must complete the data request form.

Guidance documents are used to establish guidelines for Molecular Tumor Board (MTB) recommendations for advanced cancer.

MTB guidance documents will be made available to download below.

Download Guidance MTB Documents

• Guidance Document: Off-Label Use (PDF, 114.17 KB)
• UK Molecular Tumor Genetic Testing Guideline (PDF, 184 KB)

Reference documents are used to aid Molecular Tumor Board members in meeting discussions and advanced care recommendations.

MTB reference documents will be made available for download below on this page.

Download Reference MTB Documents

• Ovarian Cancer: When to Test and Emerging Therapies - Precision Medicine Symposium 2018 (PDF, 3 MB)
• BAP1 Presentation - MTB Meeting, March 7, 2017 (PDF)
• Navigating from Somatic Tumor Testing to Germline Genetic Testing – MTB Meeting, March 21, 2017 (PDF)
• Therapeutic targeting & patient selection for cancers with homologous recombination defects – MTB Journal Club, Sept. 5, 2017

Watch MTB presentations

• Clinical Update on Breast Cancer: When to Test and Emerging Therapies
• Clinical Update on GI Cancer: When to Test and Emerging Therapies
• Clinical Update on Lung Cancer: When to Test and Emerging Therapies
• Next Generation Sequencing: What They Are & When to Order Them
• Intro to MCC Clinical Practice Guidelines

Directors	Site Leaders
Jill Kolesar, PharmD Professor, College of Pharmacy Department of Pharmacy Practice and Science	Chandler Park, MD, FACP Research Medical Director at Hardin Memorial Hospital, Central Kentucky Region UK Markey Cancer Center Research Network
Rachel Ware Miller, MD Associate Professor, Division of Gynecologic Oncology Department of Obstetrics and Gynecology
Executive Committee	Administrative Office
Susanne M. Arnold, MD Associate Director for Clinical Translation Markey Cancer Center	Marissa Schuh,  marissa.schuh@uky.edu Molecular Tumor Board Manager 1-844-622-0341
Eric B Durbin, DrPH, MS Assistant Professor, College of Medicine Division of Biomedical Informatics
Lars Wagner, MD Professor of Pediatrics, College of Medicine Chief, Pediatric Hematology and Oncology
Kurt Hodges, MD, MBA Clinical Faculty Department of Pathology, Division of Pathology and Laboratory Medicine
Ranjana Arora, MD, MPH Clinical Faculty Department of Pathology, Division of Pathology and Laboratory Medicine
Cory Vela, PharmD Clinical Pharmacy Specialist, Precision Medicine